Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
Article Information
vol. 43 no. 11 2859-2869
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 28, 2020
- Accepted August 24, 2020
- Published in print October 20, 2020.
- Published online ahead of print September 16, 2020.
Article Versions
- Previous version (September 16, 2020 - 10:10).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
Author Information
- Yan Xie1,2,3,
- Benjamin Bowe1,2,3,
- Andrew K. Gibson1,3,
- Janet B. McGill4,
- Geetha Maddukuri5,
- Yan Yan1,6 and
- Ziyad Al-Aly1,3,4,5,7⇑
- 1Clinical Epidemiology Center, Research and Development Service, VA St. Louis Health Care System, St. Louis, MO
- 2Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, MO
- 3Veterans Research & Education Foundation of St. Louis, St. Louis, MO
- 4Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO
- 5Nephrology Section, Medicine Service, VA St. Louis Health Care System, St. Louis, MO
- 6Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO
- 7Institute for Public Health, Washington University in St. Louis, St. Louis, MO
- Corresponding author: Ziyad Al-Aly, zalaly{at}gmail.com
Statistics from Altmetric.com
Article usage
In this Issue
November 2020, 43(11)
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
